Conference Overview - The fifth Synbio China conference will be held in Hangzhou on March 31 to April 1, 2026, at the Hilton Garden Inn [7][9] - The conference aims to gather 1,000 participants and is organized by Synbio Deep Wave and Jiangnan University [7][8] Venue and Accommodation - The main venue is the Hilton Garden Inn, located at 600 Jinsada Avenue, Qiantang District, Hangzhou [6][7] - Accommodation options include: - Hilton Garden Inn: 550 RMB per night including breakfast [6] - Holiday Inn: 238 RMB for a double room, excluding breakfast [6] - City Hotel: 238 RMB for a double room, excluding breakfast [6] Transportation - Transportation options to the venue include: - Taxi from Hangzhou East Station: approximately 25 minutes [4] - Metro from Hangzhou East Station: Line 1 to Jinsahu Station, about 30 minutes [4] - Taxi from Hangzhou Xiaoshan International Airport: approximately 40 minutes [4] Agenda Highlights - The conference will feature various sessions, including: - Day 1 AM: Focus on bio-manufacturing industry ecology and functional food science [10] - Day 1 PM: Specialized sessions on food and skincare [10] - Day 2 AM: Focus on functional ingredients and bio-manufacturing innovation [10] - Day 2 PM: Discussions on future food and all-age nutrition [10] Keynote Speakers - Notable speakers include: - An academic from the German Academy of Engineering discussing low-carbon bio-manufacturing technologies [14] - Experts from Jiangnan University and other institutions presenting on various bio-manufacturing topics [15][19] Industry Collaboration - The conference will facilitate networking and collaboration among industry professionals, researchers, and investors [34] - Opportunities for exhibitors and sponsors to showcase their products and services related to synthetic biology and bio-manufacturing [34]

Group 1 - The core viewpoint of the news is that New Nuo Wei's stock has experienced a significant decline, with a drop of 7.59% on February 2, leading to a trading volume of 702 million yuan [1] - As of February 2, New Nuo Wei's financing balance is 466 million yuan, which is 0.92% of its market capitalization, indicating a high level of financing activity compared to the past year [1] - The company reported a revenue of 1.593 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 7.71%, but it also recorded a net profit loss of 24.05 million yuan, a decrease of 117.26% compared to the previous year [2] Group 2 - As of January 9, the number of shareholders for New Nuo Wei decreased by 5.12% to 19,600, while the average number of circulating shares per person increased by 5.40% to 71,597 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 17.78 million shares, a decrease of 3.22 million shares from the previous period [3] - The company has distributed a total of 651 million yuan in dividends since its A-share listing, with 500 million yuan distributed over the past three years [2]

Core Viewpoint - Newnow (SZ300765, market value of 54.6 billion yuan) appointed a new general manager and board secretary, both born in the 1990s, which led to a negative market reaction, with the stock price dropping by up to 18% on January 30. Additionally, the company announced a significant expected loss for 2025, with net profit projected to decline by 416% to 575% compared to 2024 [1][11]. Management Changes - On January 30, Newnow announced the resignation of general manager Yao Bing and board secretary Dai Long, with Dai Long being appointed as the new general manager and Xu Wen as the new board secretary [1][13]. - Yao Bing, born in May 1977, will continue as chairman after stepping down as general manager. His pre-tax compensation for 2024 was 538,400 yuan [4][16]. - Dai Long, born in June 1992, has held various positions within the company since December 2016, including financial manager and board secretary. His pre-tax compensation for 2024 was 223,200 yuan [6][18]. - Xu Wen, born in April 1990, has been appointed as a board member since May 2024, but received no compensation from the company for 2024 [6][18]. Financial Performance - Newnow's main business focuses on biopharmaceuticals and functional foods, with a significant decline in performance expected for 2025. The company forecasts a net loss of 170 million to 255 million yuan, a decrease of 416% to 575% compared to 2024 [9][21]. - The projected net profit for 2025, excluding non-recurring items, is expected to be a loss of 210 million to 315 million yuan, representing a decline of 596% to 844% from the previous year [10][22]. - The reasons for the expected decline include increased R&D expenses due to progress in multiple products, losses from the acquisition of a controlling stake in Giant Bio, and reduced profit margins in the functional raw materials business [21][22]. - Newnow's net profits for the years 2022 to 2024 were 726 million yuan, 434 million yuan, and 53.726 million yuan, respectively, indicating a trend of significant decline over three consecutive years [21][22].

Group 1 - New CEO and Secretary appointed at XinNuoWei, both born in the 1990s, leading to a negative market reaction with a stock price drop of up to 18% [1][10] - The company announced a significant expected net profit loss for 2025, projecting a decline of 416% to 575% compared to 2024 [1][12] - The new CEO, Dai Long, has been with the company since 2016 and previously held multiple roles, while the new Secretary, Xu Wen, has a master's degree and will also serve as a board member [2][7] Group 2 - XinNuoWei's main business focuses on biopharmaceuticals and functional foods, with recent developments in ADC, mRNA vaccines, and antibody drugs [12] - The projected net profit for 2025 is expected to be between -1.7 billion to -2.55 billion, marking a significant decline from a profit of 537.26 million in 2024 [12][13] - The decline in performance is attributed to increased R&D expenses, the acquisition of a controlling stake in a subsidiary, and reduced profit margins in the functional raw materials segment [14]

Core Viewpoint - Newnow (300765) has appointed a new general manager and board secretary, both born in the 1990s, but the market reacted negatively, with the stock price dropping by up to 18% in early trading. The company also announced a significant expected net profit decline for 2025, with a decrease of 416% to 575% compared to the same period in 2024 [1]. Group 1 - The new general manager, Dai Long, born in June 1992, has a bachelor's degree and joined Newnow in December 2016, holding multiple roles including financial manager, securities affairs representative, and board secretary [1]. - Despite holding several positions, Dai Long's pre-tax compensation for 2024 was only 223,200 yuan [1]. - Newnow's main business focuses on the research, production, and sales of biopharmaceuticals and functional foods and raw materials, with a focus on cutting-edge areas such as ADC, mRNA vaccines, and antibody drugs [1].

Group 1 - The core viewpoint of the news is that XinNuoWei's stock price increased by 5.02%, reaching 39.77 CNY per share, with a trading volume of 350 million CNY and a turnover rate of 0.65%, resulting in a total market capitalization of 55.861 billion CNY [1] - XinNuoWei, established on April 5, 2006, and listed on March 22, 2019, is primarily engaged in the research, production, and sales of functional foods, with its main business revenue composition being 88.93% from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1] Group 2 - From the perspective of XinNuoWei's top ten circulating shareholders, E Fund's ETF (159915) reduced its holdings by 1.3253 million shares in the third quarter, now holding 7.868 million shares, which accounts for 0.63% of the circulating shares, with an estimated floating profit of approximately 14.9492 million CNY [2] - E Fund's ETF (159915) was established on September 20, 2011, with a latest scale of 100.446 billion CNY, achieving a year-to-date return of 3.98% and a one-year return of 60.93%, ranking 3522 out of 5546 and 730 out of 4261 respectively [2] - The fund managers, Cheng Xi and Liu Shurong, have tenures of 9 years and 8 years respectively, with Cheng Xi managing assets totaling 236.954 billion CNY and achieving a best fund return of 131.04%, while Liu Shurong manages 127.684 billion CNY with a best fund return of 194.12% [2]

Group 1 - The health industry is becoming a core pillar for high-quality economic and social development, with functional foods and skincare products being key sectors to meet public demand for a better life and establish a comprehensive health service system [1] - The Beijing University Life Sciences East China Industry Research Institute's Functional Food/Skin Care Engineering Technology Center will hold its inauguration ceremony on January 18, 2026, in Qidong, Jiangsu [1] - The center aims to promote the development of the life sciences industry, facilitate the transformation of scientific achievements, and provide public technical services as a new high-end platform [3] Group 2 - The center has made significant technological achievements in plant synthetic biology and natural product innovation, particularly in the transformation and industrialization of rare ginsenosides from ginseng and Panax notoginseng, achieving world-leading levels [3] - The center will continue to promote the application of its projects in functional foods and skincare products, addressing the slow metabolism and absorption issues of traditional ginseng saponins [3] - With the global aging population and increasing attention to public health, the functional food and skincare market is expected to experience significant growth, with a focus on natural products as essential components [10]

Group 1 - New Nuo Wei's stock price dropped by 5.21% to 40.05 CNY per share, with a trading volume of 191 million CNY and a turnover rate of 0.33%, resulting in a total market capitalization of 56.254 billion CNY [1] - The company, Shijiazhuang Yiling Pharmaceutical Co., Ltd., was established on April 5, 2006, and listed on March 22, 2019. Its main business involves the research, production, and sales of functional foods, with revenue composition being 88.93% from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1] Group 2 - Jin Yuan Shun An Fund has a significant holding in New Nuo Wei, with its Jin Yuan Shun An Medical Health Mixed A Fund (007861) increasing its stake by 13,100 shares to a total of 48,800 shares, representing 3.75% of the fund's net value, ranking as the tenth largest holding [2] - The Jin Yuan Shun An Medical Health Mixed A Fund was established on July 29, 2021, with a latest scale of 38.3683 million CNY. Year-to-date returns are 7.33%, ranking 1797 out of 8840 in its category, while the one-year return is 14.79%, ranking 5884 out of 8094. Since inception, the fund has experienced a loss of 53.75% [2] Group 3 - The fund manager of Jin Yuan Shun An Medical Health Mixed A Fund is Chen Mingjie, who has been in position for 2 years and 82 days, with a total fund asset size of 72.6952 million CNY. The best return during his tenure is 8.68%, while the worst is -24.12% [3] - Co-manager Zhang Haidong has been in position for 144 days, managing a total fund asset size of 628 million CNY, with the best return of 5.45% and the worst return of -1.14% during his tenure [3]

Group 1 - The core point of the news is that New Nuo Wei's stock price decreased by 1.22%, reaching 36.51 yuan per share, with a total market capitalization of 51.282 billion yuan [1] - New Nuo Wei is primarily engaged in the research, production, and sales of functional foods, with 88.93% of its revenue coming from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1] Group 2 - According to data, Pengyang Fund has a significant holding in New Nuo Wei, with its Pengyang Medical Health Mixed A Fund increasing its holdings by 123,500 shares to a total of 181,200 shares, representing 5.68% of the fund's net value [2] - The Pengyang Medical Health Mixed A Fund has achieved a year-to-date return of 27.83% and a one-year return of 26.14%, ranking 3388 out of 8087 and 3373 out of 8085 respectively [2] - The fund manager, Zhu Guoqing, has a tenure of 18 years and 289 days, with a total fund asset size of 862 million yuan, while the co-manager, Cui Jieming, has a tenure of 2 years and 62 days, managing assets of 147 million yuan [2]

Group 1 - The core point of the article highlights the recent decline in the stock price of New Nuo Wei, which fell by 5.36% to 37.44 CNY per share, with a trading volume of 245 million CNY and a turnover rate of 0.46%, resulting in a total market capitalization of 52.588 billion CNY [1] - New Nuo Wei, officially known as Shiyao Innovation Pharmaceutical Co., Ltd., is based in Shijiazhuang, Hebei Province, and was established on April 5, 2006. The company went public on March 22, 2019, and its main business involves the research, development, production, and sales of functional foods [1] - The revenue composition of New Nuo Wei is primarily from functional foods and raw materials at 88.93%, followed by biopharmaceuticals at 8.91%, and other sources at 2.16% [1] Group 2 - From the perspective of major fund holdings, data indicates that a fund under Jianxin Fund has a significant position in New Nuo Wei. Jianxin Medical Health Industry Stock A (008923) increased its holdings by 590,300 shares in the third quarter, bringing the total to 1.4473 million shares, which constitutes 4.74% of the fund's net value, ranking it as the seventh-largest holding [2] - Jianxin Medical Health Industry Stock A (008923) was established on December 28, 2021, with a current scale of 702 million CNY. Year-to-date returns are at 41.64%, ranking 1006 out of 4197 in its category; over the past year, returns are 40.12%, ranking 959 out of 4179; and since inception, returns are 39.64% [2]